Aktiesnakken — Februar 2010
-
så blev der stille
-
så går vi igang
-
CEO igang
-
Overall the huntexil was very well tolerated
-
with a safety profile like placebo
-
Topline results præsenteres
-
standard phase 3 study design
-
3 arme
-
437 patienter totalt.... randomised, 3 gruper med 144 148 og 145 i hver
-
5 hhv 14 trak sig fra hutexil armene
-
15 fra placebo
-
There was a suspsicion of a drug related death....but it turned to be related to placebo
-
statistik for de 3 arme gennemgås... mht demografi. ser ret ens ud.
-
Primary endpoint: significant improvement of voluntary movements.
-
den lave dosisgruppe er ikke signifikant forskellig fra placebo
-
den høje dosis er derimod
-
det samme billede mht. doser når det kommer til "Motor function" (includes voluntary and involuntary movement)
-
div vurdering af symptomer gennemgås.
-
der var noget frygt mht. "chorea" (hvad det så er) men den viste sig ubegrundet
-
Safety profile:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind